Table 2.
The clinical intervention trial of vitamins and Parkinson's disease.
| Vitamins | Authors | Patients | Treatment | Conclusions |
|---|---|---|---|---|
| Vitamin C | Nagayama et al. [50] | 67 elderly PD patients | 200 mg ascorbic acid | Ascorbic acid can improve levodopa absorption in elderly PD patients |
| Vitamin E | Parkinson Study Group (DATATOP study) [76] | 800 untreated and early PD patients | Deprenyl 10 mg/d and/or tocopherol (vitamin E) 2000 IU/d | There was no effect of tocopherol on PD |
| Parkinson Study Group (DATATOP study) [124] | 800 untreated and early PD patients | Deprenyl 10 mg/d and/or tocopherol (vitamin E) 2000 IU/d | Alpha-tocopherol did not improve clinical features in patients with Parkinson's disease | |
| Vatassery et al. (DATATOP study) [83] | n = 18 (vitamin E group)/n = 5 (placebo group) | Tocopherol (vitamin E) 2000 IU/d | Treatment with vitamin E significantly increased the alpha-tocopherol concentrations in cerebrospinal fluid | |
| Taghizadeh et al. [125] | n = 30 (vitamin E group)/n = 30 (placebo group) | 1000 mg omega-3 fatty acids plus 400 IU vitamin or placebo | Omega-3 and vitamin E cosupplementation in PD patients improved UPDRS compared with the placebo | |
| Vitamin D | Suzuki et al. [113] | n = 56 (vitamin D3 group)/n = 58 placebo group) | Vitamin D3 1200 IU/d or placebo for 12 months | Vitamin D3 prevented the deterioration of the PD and especially patients with FokI TT genes |
| Sato et al. [126] | n = 43 (vitamin D group)/n = 43 (placebo group) | 1α(OH)D3 1 μg/d or placebo for 12 months | 1alpha-hydroxyvitamin D3 supplements can reduce the risk of hip and other nonvertebral fractures in PD patients |